VRNA VERONA PHARMA PLC revenue, earnings and financials
For the quarter ended June 30, 2025, VERONA PHARMA PLC reported revenue of $103M, net income of $11.9M and diluted EPS of $0.02; over the last four quarters revenue was $222M and net income −$81.2M; for the fiscal year ended December 2024 revenue was $42.3M.
VRNA annual revenue and earnings
- Fiscal year ended Dec 2024: revenue $42.3M, gross profit n/a, operating income −$155M, net income −$173M (margin -410.2%), EPS −$0.27
- Fiscal year ended Dec 2023: revenue $0, gross profit $0, operating income −$67.6M, net income −$54.4M (margin n/a), EPS −$0.09
- Fiscal year ended Dec 2022: revenue $458K, gross profit $112K, operating income −$75.8M, net income −$68.7M (margin -15000.2%), EPS −$0.13
- Fiscal year ended Dec 2021: revenue $40.0M, gross profit $40.0M, operating income −$73.3M, net income −$55.6M (margin -138.9%), EPS −$0.12
VRNA quarterly revenue and earnings
- Quarter ended Jun 30, 2025: revenue $103M, net income $11.9M, EPS $0.02
- Quarter ended Mar 31, 2025: revenue $76.3M, net income −$16.3M, EPS −$0.02
- Quarter ended Dec 31, 2024 (from the annual report): revenue $36.7M, net income −$33.8M, EPS −$0.05
- Quarter ended Sep 30, 2024: revenue $5.62M, net income −$43.0M, EPS −$0.07
- Quarter ended Jun 30, 2024: revenue $0, net income −$70.8M, EPS −$0.11
- Quarter ended Mar 31, 2024: revenue $0, net income −$25.8M, EPS −$0.04
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$14.1M, EPS −$0.03
- Quarter ended Sep 30, 2023: revenue $0, net income −$14.7M, EPS −$0.02
- Quarter ended Jun 30, 2023: revenue n/a, net income −$8.81M, EPS −$0.01
- Quarter ended Mar 31, 2023: revenue n/a, net income −$16.7M, EPS −$0.03
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$10.5M, EPS −$0.01
- Quarter ended Sep 30, 2022: revenue $0 (down 100.0% year over year), net income −$15.6M, EPS −$0.03
- Quarter ended Jun 30, 2022: revenue n/a, net income −$17.8M, EPS −$0.04
- Quarter ended Mar 31, 2022: revenue n/a, net income −$24.8M, EPS −$0.05
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$23.3M, EPS −$0.04
- Quarter ended Sep 30, 2021: revenue $40.0M, net income $11.1M, EPS $0.02
- Quarter ended Jun 30, 2021: revenue n/a, net income −$22.1M, EPS −$0.05
- Quarter ended Mar 31, 2021: revenue n/a, net income −$21.3M, EPS −$0.05
VRNA cash flow, buybacks and dividends
- Fiscal year ended Dec 2024: operating cash flow −$122M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$50.2M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$59.9M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$33.3M, share buybacks n/a
VRNA balance sheet
- Jun 30, 2025: cash $438M, total assets $573M, total liabilities $295M, shareholders' equity $278M, long-term debt $242M
- Mar 31, 2025: cash $401M, total assets $526M, total liabilities $299M, shareholders' equity $227M, long-term debt $242M
- Dec 31, 2024: cash $400M, total assets $474M, total liabilities $270M, shareholders' equity $205M, long-term debt $120M
- Sep 30, 2024: cash $336M, total assets $382M, total liabilities $251M, shareholders' equity $130M, long-term debt $120M
- Jun 30, 2024: cash $405M, total assets $434M, total liabilities $266M, shareholders' equity $168M, long-term debt $120M
- Mar 31, 2024: cash $255M, total assets $290M, total liabilities $64.9M, shareholders' equity $225M, long-term debt $48.5M
- Dec 31, 2023: cash $272M, total assets $308M, total liabilities $58.8M, shareholders' equity $249M, long-term debt $48.4M
- Sep 30, 2023: cash $257M, total assets $292M, total liabilities $28.9M, shareholders' equity $264M, long-term debt $19.9M
What is VRNA's revenue?
VERONA PHARMA PLC reported $222M of revenue over its last four quarters, through June 30, 2025.
Is VRNA profitable?
No. VERONA PHARMA PLC lost $81.2M over the last four quarters.
What is VRNA's EPS?
Diluted earnings per share over the last four quarters were −$0.12; $0.02 in the latest quarter.